Olezarsen + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Hypertriglyceridemia
Conditions
Severe Hypertriglyceridemia
Trial Timeline
Aug 31, 2022 → Sep 12, 2025
NCT ID
NCT05552326About Olezarsen + Placebo
Olezarsen + Placebo is a phase 3 stage product being developed by Ionis Pharmaceuticals for Severe Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05552326. Target conditions include Severe Hypertriglyceridemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05610280 | Phase 3 | Completed |
| NCT05552326 | Phase 3 | Completed |
| NCT05355402 | Phase 2 | Completed |
| NCT05079919 | Phase 3 | Completed |
| NCT04568434 | Phase 3 | Completed |
Competing Products
20 competing products in Severe Hypertriglyceridemia